Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country?

AIDS Res Ther. 2019 Aug 14;16(1):19. doi: 10.1186/s12981-019-0234-2.

Abstract

Brazil is a low-and-middle income country (LMIC) that, despite having a large population and continental dimensions, has been able to successfully fight HIV/AIDS through a number of governmental and societal measures. These included an early response to the epidemic, the development of a universal and free public health system, incisive discussions with pharmaceutical companies to reduce antiretroviral (ARV) drug prices, investments towards the development of generic drugs and compulsory licensing of ARVs. Through such measures, Brazil is among the leading LMIC towards achieving the 90-90-90 UNAIDS goals in the years to come. In this review, we analyze Brazil's progress throughout the HIV/AIDS epidemic to achieve state-of-the-art ARV treatment and to reduce AIDS mortality in the country. The top-quality HIV/AIDS research in Brazil towards HIV prophylactic and functional cure, the next step towards the economic sustainability of the battle against HIV, is also discussed.

Keywords: AIDS; Antiretroviral treatment; Brazil; HIV; HIV cure.

Publication types

  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / economics*
  • Acquired Immunodeficiency Syndrome / prevention & control
  • Anti-Retroviral Agents / economics*
  • Anti-Retroviral Agents / therapeutic use*
  • Brazil
  • Delivery of Health Care / economics
  • Delivery of Health Care / standards
  • Health Policy*
  • Health Services Accessibility
  • Humans
  • Research / economics
  • Research / legislation & jurisprudence

Substances

  • Anti-Retroviral Agents